Reprinted with the kind permission of Life Extension.
October 25 2017. The results of a meta-analysis that were published on September 22, 2017 in Nutrition & Metabolism add evidence to an association between supplementing with resveratrol and improved management of type 2 diabetes.
“As a potent antioxidant, resveratrol is a plant-derived polyphenolic compound that possesses anti-inflammatory, antiplatelet aggregation, anti-carcinogenic, cartilage-protective, and anti-aging properties,” Ling Li of Southeast University in Nanjing, China and colleagues write. “Some studies have revealed that resveratrol administration improves insulin sensitivity in diabetic rats and patients with type 2 diabetes mellitus.”
For their analysis, Dr Li and associates selected nine randomized, controlled trials involving a total of 283 type 2 diabetics that compared levels of glucose, insulin and other factors among participants who received resveratrol to those who received a placebo or a control group of diabetics. Resveratrol doses ranged from 8 milligrams (mg) to 3,000 mg per day, administered during a period of 4 weeks to one year.
The analysis concluded that resveratrol supplementation was associated with significantly reduced insulin levels and insulin resistance. Fasting plasma glucose was reduced by an average of 5.2 milligrams per deciliter (mg/dL) among those who received resveratrol compared to placebo or control groups. Further analysis determined that only 100 mg or higher doses of resveratrol were associated with lower glucose levels. Blood pressure mildly improved among those treated with resveratrol.
“Resveratrol supplementation may improve fasting plasma glucose, HOMA-IR (a measure of insulin resistance), and insulin in diabetic patients,” the authors conclude. “The dose and/or duration of treatment with resveratrol might also influence the effect of resveratrol on glucose homeostasis. Therefore, studies with durations longer than three months should be designed to confirm the efficacy of resveratrol and determine the appropriate dosage regimen in managing type 2 diabetes mellitus.”